Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1Phase 1/2 1

Status

Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Uterine Cervical Neoplasms 1Ovarian Neoplasms 1Multiple Myeloma 1Lung Neoplasms 1Head and Neck Neoplasms 1Esophageal Neoplasms 1Endometrial Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Breast Neoplasms 1

Interventions

Carboplatin 190Cisplatin 156Pemetrexed 151Paclitaxel 127Docetaxel 109pembrolizumab 87Gemcitabine 73Erlotinib Hydrochloride 44Radiotherapy 39Vinorelbine 35Gefitinib 34durvalumab 31Bevacizumab 28Nivolumab 26Drug Therapy 23atezolizumab 22osimertinib 19130-nm albumin-bound paclitaxel 19tislelizumab 16Crizotinib 16Radiosurgery 15Etoposide 14Surgical Procedures, Operative 11Afatinib 11Ipilimumab 10icotinib 9aumolertinib 9Albumin-Bound Paclitaxel 9Specimen Handling 8Observation 8

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 3 × Carcinoma, Non-Small-Cell Lung × Diphenhydramine × Clear all
NCT06704620 2024-12-16

Study of Tislelizumab and Platinum-based Chemotherapy Combination With H1 Receptor Antagonist(Diphenhydramine)in Advanced and Metastatic Non-Small Cell Lung Cancer

Tianjin Medical University Cancer Institute and Hospital

Phase 3 Not yet recruiting
430 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung

Data powered by HemOnc (CC BY 4.0) Colophon ⚡